Urolithin A and Immune Aging: What the 2025 Inflammaging Research Shows
Key takeaways
- Inflammaging is chronic, sterile, low-grade inflammation that accumulates with age and is closely tied to immune-cell decline.
- Immune cells are energy-hungry, and their mitochondria, kept healthy in part by mitophagy, help determine how well T cells and NK cells function.
- A 2025 randomized, placebo-controlled trial (1,000 mg/day standardized Urolithin A, ~28 days, adults 45-70) reported shifts in naive-like CD8+ T cells, the exhaustion marker TOX, NK cells, PGC-1a, and IL-2.
- This is a single small study measuring cellular markers, not clinical outcomes, so results are promising but preliminary.
- A Urolithin A supplement is best framed as support for normal immune-cell and mitochondrial function during healthy aging, used alongside professional guidance, never to treat or prevent illness.
What "inflammaging" and immune aging actually are
Search interest in urolithin a immune inflammaging has climbed for a reason: researchers increasingly view chronic, low-grade inflammation as a central feature of biological aging. The term "inflammaging" was popularized to describe a background hum of sterile inflammation that rises with age even without active infection, and that tracks with age-associated decline. You can read the foundational framing in Franceschi and Campisi's widely cited overview in The Journals of Gerontology (2014).
Alongside inflammaging runs immunosenescence, the gradual remodeling of the immune system. Over decades, the body produces fewer fresh, "naive" T cells ready to learn new threats, while more cells drift toward an exhausted or senescent state. Ferrucci and Fabbri's review in Nature Reviews Cardiology (2018) connects this chronic inflammatory tone to frailty and cardiovascular aging. The practical takeaway for healthy adults is simple: supporting the everyday function of immune cells is part of the broader healthy-aging picture, not a substitute for medical care.
The mitochondria-immune cell connection
Immune cells are among the most metabolically demanding cells in the body. When a T cell is called to act, it has to rapidly rebuild its metabolism, and that pivot runs on mitochondria. Reviews of mitochondria during T-cell aging (2023) describe how mitochondrial output shapes whether a T cell stays fit and flexible or slides toward dysfunction.
Quality control matters as much as quantity. Mitophagy, the housekeeping process that clears out worn, underperforming mitochondria so healthier ones can take over, appears to be important for keeping immune cells energetically nimble. Work on mitochondrial quality control in ageing T cells (EMBO Reports, 2025) frames this cleanup as part of what keeps aging T cells functional. And a striking mouse study in Science (2020) showed that T cells with deliberately broken mitochondria could drive systemic inflammation and features of premature aging, underscoring how tightly immune-cell mitochondria and inflammaging are linked.
This is where Urolithin A enters the story. Urolithin A is a compound the gut microbiome makes from ellagitannins found in foods like pomegranates and walnuts, though many people produce little of it. Standardized Urolithin A is studied specifically as a mitophagy activator. Its first-in-human safety and biomarker work appeared in Nature Metabolism (2019), and a later randomized trial in Cell Reports Medicine (2022) reported changes in muscle and mitochondrial biomarkers in middle-aged adults. Those studies set up an obvious question: if Urolithin A supports mitochondrial housekeeping, might that show up in the energy-hungry immune system too?
What the 2025 Urolithin A immune trial found
In 2025, a research team put that question to a direct test. The study published in Nature Aging was a randomized, double-blind, placebo-controlled trial of 50 healthy adults aged 45-70, randomized 1:1 to take 1,000 mg of standardized Urolithin A daily for about four weeks or placebo. Rather than tracking colds or clinical outcomes, the researchers looked deep inside immune cells to ask whether their mitochondrial and functional profile shifted.
The reported changes point in a consistent direction: toward immune cells that look metabolically fitter and less exhausted. Here is a summary of the main immune findings.
| Immune measure | What the trial reported with Urolithin A | Why it may matter for healthy aging |
|---|---|---|
| Naive-like CD8+ T cells | Modest increase versus placebo | Naive cells are the "fresh recruits" that tend to decline with age |
| TOX (exhaustion marker) | Lower expression in CD8+ T cells | Suggests a less terminally exhausted T-cell phenotype |
| NK cells (CD56dim CD16bright) | Increased versus placebo | This subset is associated with mature effector function |
| PGC-1a in CD8+ T cells | Stronger expression after the intervention | PGC-1a is a master regulator of mitochondrial biogenesis |
| Fatty-acid oxidation capacity (CD8+) | Higher | Points to a shift toward efficient mitochondrial metabolism |
| IL-2 (circulating) | Lower | A change in immune signaling; overall pro-inflammatory markers were unchanged |
Read together, the pattern is one of immune cells nudged toward a more youthful-looking, mitochondrially fitter profile over 28 days, consistent with Urolithin A's proposed role in mitophagy.
How to read these results honestly
Enthusiasm should be matched with honesty about the evidence grade. This is a single, small, four-week trial in 50 people. It measured biomarkers and cell phenotypes, not whether participants got sick less often, aged more slowly, or lived longer, none of which this study was designed to show. Several effect sizes were modest, the follow-up was short, and no single study, however well designed, is the last word. Findings like these need to be replicated in larger, longer, and more diverse groups before anyone can say what they mean for day-to-day health.
So the accurate summary is: promising, biologically coherent, and early. It is reasonable to be interested in Urolithin A as an ingredient that may support normal immune-cell and mitochondrial function during healthy aging. It is not reasonable, or legal, to treat it as something that boosts immunity against disease, treats infections, or reverses immune aging. Those are claims the science does not support and that supplements are not intended to make.
Where a Urolithin A supplement may fit for healthy-aging immune support
If you are a generally healthy adult already thinking about mitochondrial health, exercise recovery, and aging well, a standardized Urolithin A supplement is one option to discuss with your healthcare provider as part of that routine. The dose used across much of this research, including the 2025 immune trial, is 1,000 mg per day, which is why SOMA Urolithin A gummies are formulated at that 1,000 mg dose. Framing matters: think of it as everyday support for normal cellular and mitochondrial function, not as a shield against illness.
A supplement is also only one input. The foundations of resilient immune aging remain unglamorous and well established: regular physical activity, adequate protein, sleep, managing stress, not smoking, and staying current with the preventive care your clinician recommends. Urolithin A, if you choose to use it, sits on top of those basics, not in place of them. And because individual health situations vary widely, especially if you take medications, are pregnant or nursing, or have a diagnosed immune condition, the right move is to loop in a qualified professional before starting.
Frequently asked questions
Does Urolithin A boost your immune system?
No supplement should be described that way. The 2025 trial reported changes in immune-cell markers and mitochondrial fitness in healthy midlife adults, which is different from "boosting immunity" against disease. It is more accurate to say Urolithin A is being studied for whether it supports normal immune-cell and mitochondrial function during healthy aging.
What is inflammaging, in plain terms?
Inflammaging is chronic, low-grade inflammation that builds up as we age even without an active infection. It is associated with the gradual decline of immune-cell function and with age-related frailty, which is why researchers study interventions that touch the mitochondrial health underlying it.
How strong is the evidence for Urolithin A and immune aging?
Early. The main human immune data come from one randomized, placebo-controlled trial of 50 adults over about four weeks, measuring cellular biomarkers rather than clinical outcomes. It is encouraging and mechanistically sensible, but it needs replication in larger and longer studies before firm conclusions can be drawn.
What dose was used in the research?
The 2025 immune trial, and much of the prior human work, used 1,000 mg of standardized Urolithin A per day. SOMA Urolithin A gummies are formulated at that same 1,000 mg dose.
Should I take Urolithin A if I have an immune condition?
Talk to your healthcare provider first. Urolithin A is a wellness supplement intended to support normal function in healthy adults, not to treat, prevent, or manage any immune disease. If you have a diagnosed condition or take medication, professional guidance should come before any supplement.
Support your cellular health, every day
SOMA delivers a high-potency 1,000 mg dose of Urolithin A in one simple daily gummy — no guesswork, no converter-status lottery.
Shop SOMA Urolithin A Gummies →These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.